Objective:

To evaluate the experience of the chronic patient treated with PCSK9 inhibitors of a cohort of real clinical practice according to the pharmaceutical care model (AF) based on the concept Capacity-Motivation-Opportunity (CMO).

Methods:

One-way cross-sectional study that included adult patients with hypercholesterolemia in treatment with any PCSK9 inhibitor who took at least 6 months of treatment and who followed up in external AF consultations during the month of April 2019. Demographic variables (sex and age), clinics (levels of total cholesterol and LDL-c), pharmacotherapeutic (number of prescribed concomitant medications and type of anti-PCSK9) and related to AF (level of stratification according to the Chronic Patient's Selection and Pharmaceutical Care Model Spanish Pharmacy Hospital). The assessment of the patient's experience was carried out through the IEXPAC questionnaire via telephone, by a pharmacist different from the one who followed up.

Results:

28 patients (67.9% male) were included, with a middle age of 63 (IQR: 54-72). Pharmaco-therapeutic data show a polymedicated population. 80.7% were treated with alirocumab and 19.3% evolocumab. Through the concept of Capacity, the study population was stratified resulting in 57.2% of level 3, while 21.4% belonged to levels 1 and 2 respectively. The IEXPAC questionnaire gave us a high overall score (6.9±1.6).

Conclusions:

The evaluation of pharmaceutical care based on the CMO methodology in chronic patients treated with PCSK9 inhibitors meets a high expectation level at each identified interaction point.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )